Categories: Health

Carl H. Sharperson III Joins MATTER Board of Directors

 | Source: MATTER

MINNEAPOLIS, MN , Dec. 03, 2025 (GLOBE NEWSWIRE) — MATTER, a Minnesota-based global NGO, today announced the appointment of Carl H. Sharperson III to its Board of Directors.

Sharperson currently serves as a Senior Corporate Account Executive at GitHub, a subsidiary of Microsoft, where he helps companies modernize their software engineering practices with artificial intelligence. He holds a BBA in Marketing from Savannah State University in Savannah, Georgia, and an MBA in Finance from the University of Miami Herbert Business School.

Carl’s connection to MATTER began in 2023 when he traveled to Victoria Falls, Zimbabwe, to visit the MATTER Career Readiness Institute. During that trip, he worked with students on interview skills and career readiness, an experience that deepened his passion for creating opportunities for young people to thrive where they live. Each year, he participates in an overseas short-term mission trip, with past travel including Istanbul (Turkey), the Comoros Islands in East Africa, Yogyakarta (Indonesia), Madrid (Spain), Limassol (Cyprus), Varanasi (India), and Cairo (Egypt). Carl also serves as a deacon at River Valley Church’s City campus in Minneapolis.

“I am honored to join the MATTER Board of Directors,” said Sharperson. “Having seen firsthand the impact of MATTER’s work in Zimbabwe, I am inspired by their commitment to innovation, sustainability, and empowering local leaders. I’m excited to bring my experience in technology, business, and global missions to help MATTER expand its impact around the world.”

“Carl brings a powerful blend of corporate expertise, global perspective, and a heart for people that fits perfectly with where MATTER is headed,” said Quenton Marty, CEO of MATTER. “His passion for equipping the next generation and his experience at the intersection of technology and innovation will be a tremendous asset as we continue to grow MATTER’s social enterprise engine and advance projects that improve communities around the world.”

Carl Sharperson III

About MATTER

MATTER, a Minnesota-based global NGO, brings together the best companies, experts, problem solvers and above all, doers, to launch projects that improve communities. This collaborative movement has inspired solutions in health access, providing beneficial meals for children and families, regenerative agriculture, and student-centered education, collectively impacting more than 54 million lives. MATTER’s guiding belief is encapsulated in the simple yet powerful expression, YOU MATTER. 

Press inquiries

MATTER
https://www.matter.ngo
Brian Numainville
brian@matter.ngo
612-467-9141 

GlobeNews Wire

Recent Posts

FemiCore (Official Website & Authenticity Notice 2026) Counterfeit Risks and What Consumers Should Know

New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- The women's health supplement market…

18 hours ago

Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance

BEIJING, June 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Hitch Open Ping-Pong Embodied AI Challenge…

18 hours ago

Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000

MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

18 hours ago

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies [NSE: HEXT], a…

20 hours ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

21 hours ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

21 hours ago